BACKGROUND: Sinonasal undifferentiated carcinoma (SNUC) remains a poorly characterized malignancy at both the clinical and molecular level, and, consequently, the optimal treatment strategy remains undefined. METHODS: We used a mass spectroscopy-based approach (Sequenom) to evaluate 95 hallmark single nucleotide variations (SNVs) within 12 oncogenes or tumor suppressor genes (AKT, BRAF, CDK4, Beta-catenin, epidermal growth factor receptor [EGFR], FBXW7, JAK2, c-KIT, KRAS, PDGFR, PI3K, and vascular endothelial growth factor [VEGF]) in 13 histologically confirmed SNUC cases. RESULTS: None of the samples demonstrated activating mutations in any of the 95 SNVs. CONCLUSION: Select clinically relevant activating genomic mutations were not identified in the 13 patient samples. However, polymorphisms were noted within the promoter region of VEGF. These may merit future studies as predictive biomarkers for treatment response or overall survival. Additionally, future studies focusing on larger tumor sets and utilizing whole genome or exome sequencing may help define genetic aberrations in SNUC that can be clinically targeted with available or emerging biological agents.
BACKGROUND:Sinonasal undifferentiated carcinoma (SNUC) remains a poorly characterized malignancy at both the clinical and molecular level, and, consequently, the optimal treatment strategy remains undefined. METHODS: We used a mass spectroscopy-based approach (Sequenom) to evaluate 95 hallmark single nucleotide variations (SNVs) within 12 oncogenes or tumor suppressor genes (AKT, BRAF, CDK4, Beta-catenin, epidermal growth factor receptor [EGFR], FBXW7, JAK2, c-KIT, KRAS, PDGFR, PI3K, and vascular endothelial growth factor [VEGF]) in 13 histologically confirmed SNUC cases. RESULTS: None of the samples demonstrated activating mutations in any of the 95 SNVs. CONCLUSION: Select clinically relevant activating genomic mutations were not identified in the 13 patient samples. However, polymorphisms were noted within the promoter region of VEGF. These may merit future studies as predictive biomarkers for treatment response or overall survival. Additionally, future studies focusing on larger tumor sets and utilizing whole genome or exome sequencing may help define genetic aberrations in SNUC that can be clinically targeted with available or emerging biological agents.
Authors: Christopher A French; Jeffery L Kutok; William C Faquin; Jeffrey A Toretsky; Cristina R Antonescu; Constance A Griffin; Vania Nose; Sara O Vargas; Mary Moschovi; Fotini Tzortzatou-Stathopoulou; Isao Miyoshi; Antonio R Perez-Atayde; Jon C Aster; Jonathan A Fletcher Journal: J Clin Oncol Date: 2004-10-15 Impact factor: 44.544
Authors: Emily D Tanzler; Christopher G Morris; Christine A Orlando; John W Werning; William M Mendenhall Journal: Head Neck Date: 2008-05 Impact factor: 3.147
Authors: Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544
Authors: Molly E Heft Neal; Andrew C Birkeland; Apurva D Bhangale; Jingyi Zhai; Aditi Kulkarni; Susan K Foltin; Brittany M Jewell; Megan L Ludwig; Lisa Pinatti; Hui Jiang; Jonathan B McHugh; Lawence Marentette; Erin L McKean; J Chad Brenner Journal: BMC Cancer Date: 2021-05-29 Impact factor: 4.430